Posted: 7 month(s) and 26 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: fidel

This small biopharma company was just given the nod by FDA to submit a New Drug Application for formal approval. Successfully obtaining the necessary Phase III trial results in order to do so. They are bringing a new bug resistant antibiotic to the market. Cethromycin has been shown to treat Community aquired Pneumonia, Strep, and MRSA. Older antibiotics have quit working effectively against these bugs,MRSA is killing people left and right in our nations hospital,MRSA in case you are not aware is a bug that has developed in most the hospitals where you go in to have your tonsils removed and catch MRSA and die because very few of the current medicines are any longer effectice against these viral infections. There is a huge market for this. I listened to there Conference call this week,there were half a dozen analysts there asking many critical questions of the drugs developer Dr Flavin. They stated that they expected the NDA to approved in 3Q sometime. A number of large bio companies are currently in talks with ADLS to partner up and help bring the drug to market, and to distibute it.. Once a partner is chosen in the next 30 to 60 days,the stock price will rise to about $4.00.Based on the BV of CETH when brought to market the price is expected to rise up to the $8.00 to $10 dollars range. $4.00 dollars is the current target price that the Lazard Analyst just set on Tuesday with his udgrade of ADLS to a BUY. PPS is currently at $1.23 , I own this stock realtime @ .89 cents. 

This an excellent investment opportunity with very little downleg risks and an excellent short, near and long term potential. I expect the stock to go up to $at least $2.00 this week with the publication of the recent Upgrade by Lazard.

Add Comment / Rating